As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper ...

Minnesota lawmakers are once again calling on insurance companies to cover anti-obesity medications like Ozempic and Wegovy ...

Two recent documents—one from the FDA, the other from a commission organized by The Lancet Diabetes & Endocrinology—indicate ...

Obesity and pharmacology experts are warning about hidden safety risks and efficacy issues for many types of medications in ...

Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug ...

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

As drugmakers Novo Nordisk and Eli Lilly struggled to keep up with enormous demand for their diabetes and obesity drugs, the ...

Novo Nordisk has launched a direct-to-consumer (DTC) option for uninsured or under-insured people wanting to access its GLP-1 ...

A study published on Tuesday in 'The Lancet' warns of the escalation of the obesity and overweight pandemic if no action is ...

The sale of compounded versions of Eli Lilly's LLY.N rival obesity and diabetes drugs, Zepbound and Mounjaro, was banned in ...